CanID: a robust and accurate RNAseq Expression-based diagnostic classification scheme for pediatric malignancies

Cancer subtype classification is critical for precision therapy and there is a growing trend of augmenting histopathology testing procedures with omics-based machine learning classifiers. However, analytical challenges remain for pediatric cancer on the scope and precision of the current classifiers as well as the evolving subtype standardization. To address these challenges, we built Cancer Identification or CanID, a stacked ensemble machine learning classification scheme, using the transcriptomic features derived from gene-level RNA sequencing count data as the sole input. CanID was developed primarily from 3203 pediatric cancer samples of 13 solid tumor subtypes and 38 hematologic malignancy subtypes with subtype labels curated without the use of RNA-seq data. The accuracies of independent testing in three independent or external data sets for Solid Tumor and Hematologic Malignancy are 99% and 92-93%, respectively. Notably, CanID was able to classify subtypes challenging for clinical histology evaluation and was robust to both biological and technical challenges, including differences in data collection protocols, class imbalance, potential mislabeled training samples and classes unobserved in training. The high accuracy, robustness, biological interpretability of this transcriptome-based classification scheme represents a valuable approach to advance tumor diagnosis and clinically meaningful stratification of tumor types. CanID can be accessed on GitHub at https://github.com/chenlab-sj/CanID .